Sponsored Symposium


  • Sep.26 (THU)
  • Sep.27 (FRI)

Sep.26(THU)

Satellite Symposium 1 (SL01)

First-line treatment in metastatic colorectal cancer
Date & Time Sep. 26 (Thu), 08:50-09:30 Venue Room E
Chair(s)
  • Jong Gwang Kim (Kyungpook National University Hospital, Korea)
Presentation
Detail
  1. The necessity of FOLFOXIRI as first-line treatment in patients with metastatic colorectal cancer
    Yongjun Cha (National Cancer Center, Korea)

Satellite Symposium 2 (SL02)

New treatment options for NSCLC patients with METex14 skipping alterations
Date & Time Sep. 26 (Thu), 09:40-10:20 Venue Room E
Chair(s)
  • Sang-We Kim (Asan Medical Center, Korea)
Presentation
Detail
  1. New treatment options for NSCLC patients with METex14 skipping alterations
    Sun Min Lim (Yonsei Cancer Center, Korea)

Luncheon Symposium 1 (LS01)

Recent treatment update in TNBC
Date & Time Sep. 26 (Thu), 11:40-12:20 Venue Room B
Chair(s)
  • Jee Hyun Kim (Seoul National University, Seoul National University Bundang Hospital, Korea)
Presentation
Detail
  1. The Role of Pembrolizumab: Redefining treatment for early triple-negative breast cancer
    Jieun Lee (College of Medicine, The Catholic University of Korea, Korea)

Luncheon Symposium 2 (LS02)

EGFRm+ NSCLC (Osimertinib)
Date & Time Sep. 26 (Thu), 11:40-12:20 Venue Room C
Chair(s)
  • Ji-Youn Han (National Cancer Center, Korea)
Presentation
Detail
  1. Osimertinib, elevate the standard of care for EGFRm+ NSCLC
    Jeonghwan Youk (Seoul National University Hospital, Korea)

Luncheon Symposium 3 (LS03)

Push the paradigm in mBC: From guidelines to clinical practice of HER2-low
Date & Time Sep. 26 (Thu), 11:40-12:20 Venue Room D
Chair(s)
  • Seock-Ah Im (Seoul National University Hospital, Korea)
Presentation
Detail
  1. Push the paradigm in mBC: From guidelines to clinical practice of HER2-low
    Giuseppe Curigliano (European Institute of Oncology, IRCCS and Università degli Studi di Milano, Italy)

Luncheon Symposium 4 (LS04)

Redefining of management for IDH1 mutation patients with the arrival of Ivosidenib
Date & Time Sep. 26 (Thu), 11:40-12:20 Venue Room E
Chair(s)
  • Myung Ah Lee (The Catholic University of Korea Seoul St. Mary's Hospital, Korea)
Presentation
Detail
  1. Redefining of management for IDH1 mutation patients with the arrival of Ivosidenib
    Kyu-Pyo Kim (Asan Medical Center, Korea)

Satellite Symposium 3 (SL03)

State-of-the-art perioperative treatment in pancreatic cancer: What must we know in 2024?
Date & Time Sep. 26 (Thu), 12:30-13:10 Venue Room E
Chair(s)
  • Hye Jin Choi (Severance Hospital, Korea)
Presentation
Detail
  1. State-of-the-art perioperative treatment in pancreatic cance:r What must we know in 2024?
    Changhoon Yoo (Asan Medical Center, University of Ulsan College of Medicine, Korea)

Satellite Symposium 4 (SL04)

Recent treatment update in Biliary Tract Cancer
Date & Time Sep. 26 (Thu), 13:20-14:00 Venue Room E
Chair(s)
  • Myung Ah Lee (The Catholic University of Korea Seoul St. Mary's Hospital, Korea)
Presentation
Detail
  1. Leveraging the power of immunotherapy: Pembrolizumab’s breakthrough in biliary tract cancer treatment
    Minsu Kang (Seoul National University Bundang Hospital, Korea)

Satellite Symposium 5 (SL05)

Real-practice of targeting CLDN18.2-positive gastric cancer treatment
Date & Time Sep. 26 (Thu), 14:10-14:50 Venue Room E
Chair(s)
  • Jeeyun Lee (Samsung Medical Center, Korea)
Presentation
Detail
  1. Molecular targeted therapy for gastric cancer
    Hirokazu Shoji (National Cancer Center Hospital, Japan)

Satellite Symposium 6 (SL06)

Patient centricity with PHESGO: Achieving a win-win strategy
Date & Time Sep. 26 (Thu), 15:00-15:40 Venue Room E
Chair(s)
  • Kyong Hwa Park (Korea University Anam Hospital, Korea)
Presentation
Detail
  1. Patient centricity with PHESGO: Achieving a win-win strategy
    Matteo Lambertini (University of Genova, Italy)

Satellite Symposium 7 (SL07)

Palbociclib from clinical trial to Real-World in HR+/HER2- mBC treatment
Date & Time Sep. 26 (Thu), 16:30-17:10 Venue Room E
Chair(s)
  • Jin-Hee Ahn (Asan Medical Center, Korea)
Presentation
Detail
  1. Insights on Palbociclib in HR+/HER2- mBC treatment: Bridging the gap between clinical trials and real-world data
    Min Hwan Kim (Yonsei University College of Medicine, Korea)

Sep.27(FRI)

Satellite Symposium 8 (SL08)

Treatment for mCRC : Focused on FTD/TPI
Date & Time Sep. 27 (Fri), 08:40-09:20 Venue Room E
Chair(s)
  • Seung Hoon Beom (Yonsei Cancer Center, Korea)
Presentation
Detail
  1. The role of Trifluridine/Tipiracil (FTD/TPI) as third–line treatment or beyond for refractory colorectal cancer without oncogenic drivers
    Sejun Park (The Catholic University of Korea Seoul St. Mary's Hospital , Korea)

Satellite Symposium 9 (SL09)

ADC in the treatment of metastatic triple-negative breast cancer
Date & Time Sep. 27 (Fri), 09:20-10:00 Venue Room E
Chair(s)
  • Sung-Bae Kim (Asan Medical Center, Korea)
Presentation
Detail
  1. Optimal management of mTNBC: Where are we now
    Ji Yeon Kim (Samsung Medical Center, Korea)

Satellite Symposium 10 (SL10)

Current insights on Lutetium-177-PSMA-617 Radioligand Therapy for metastatic castration-resistant prostate cancer
Date & Time Sep. 27 (Fri), 10:10-10:50 Venue Room E
Chair(s)
  • Hyo Jin Lee (Chungnam National University Hospital, Korea)
Presentation
Detail
  1. 177Lu-PSMA-617: A new horizon for metastatic castration resistant prostate cancer
    Chang Gon Kim (Yonsei Cancer Center, Korea)

Luncheon Symposium 5 (LS05)

A new horizon in small cell lung cancer treatment: The promise of Lurbinectedin
Date & Time Sep. 27 (Fri), 11:50-12:30 Venue Room B
Chair(s)
  • Jin Seok Ahn (Samsung Medical Center, Korea)
Presentation
Detail
  1. A new horizon in small cell lung cancer treatment: The promise of Lurbinectedin
    Jacob Sands (Dana-Farber Cancer Institute, USA)

Luncheon Symposium 6 (LS06)

Ribociclib and its role in HR+/HER2- Breast cancer treatment
Date & Time Sep. 27 (Fri), 11:50-12:30 Venue Room C
Chair(s)
  • Kyung Hae Jung (Asan Medical Center, Korea)
Presentation
Detail
  1. Survival innovation in HR+/HER2- Breast cancer treatment: Key clinical data of Ribociclib and insights for clinical practice
    Jee Hyun Kim (Seoul National University, Seoul National University Bundang Hospital, Korea)

Luncheon Symposium 7 (LS07)

Lazertinib: The dawn of a new era in EGFR-mutant NSCLC 1L treatment
Date & Time Sep. 27 (Fri), 11:50-12:30 Venue Room D
Chair(s)
  • Myung-Ju Ahn (Samsung Medical Center, Korea)
Presentation
Detail
  1. Lazertinib: The dawn of a new era in EGFR-mutant NSCLC 1L treatment
    Beung-Chul Ahn (National Cancer Center, Korea)

Satellite Symposium 11 (SL11)

Journey for HR+/HER2- breast cancer patients with Abemaciclib as standard treatment : Final OS results of Monarch 3 and landmark 5-year data of Monarch E
Date & Time Sep. 27 (Fri), 12:40-13:20 Venue Room E
Chair(s)
  • Joo Hyuk Sohn (Severance Hospital, Korea)
Presentation
Detail
  1. Journey for HR+/HER2- breast cancer patients with Abemaciclib as standard treatment : Final OS results of Monarch 3 and landmark 5-year data of Monarch E
    Kyung-Hun Lee (Seoul National University Hospital, Korea)

Satellite Symposium 12 (SL12)

Establishing a new treatment paradigm in advanced urothelial cancer
Date & Time Sep. 27 (Fri), 13:30-14:10 Venue Room E
Chair(s)
  • Sang Joon Shin (Severance Hospital, Korea)
Presentation
Detail
  1. A new treatment paradigm in advanced urothelial carcinoma with enfortumab vedotin
    Inkeun Park (Asan Medical Center, Korea)

Satellite Symposium 13 (SL13)

Immuno-therapy OPDIVO gastric cancer session
Date & Time Sep. 27 (Fri), 15:10-15:50 Venue Room E
Chair(s)
  • Minkyu Jung (Yonsei Cancer Center, Korea)
Presentation
Detail
  1. 1.Optimal application of front-line nivolumab plus chemotherapy in patients with advanced gastric cancer in clinical practice
    Hyung-Don Kim (Asan Medical Center, Korea)
  2. 2. Consensus on PD-L1 28-8 IHC CPS interpretation in gastric cancer
    Yoonjin Kwak (Seoul National University Hospital, Korea)

Satellite Symposium 14 (SL14)

Consideration treatment sequencing for ALK+ NSCLC
Date & Time Sep. 27 (Fri), 16:00-16:40 Venue Room E
Chair(s)
  • Jin Seok Ahn (Samsung Medical Center, Korea)
Presentation
Detail
  1. Real-world treatment patterns and effectiveness of subsequent treatments following 1L brigatinib from ALTA-1L
    Jang Ho Cho (The Catholic University of Korea Incheon St. Mary's Hospital, Korea)